Osteometabolix Pharmaceuticals
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.osteometabolix.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Osteometabolix Pharmaceuticals
OMX is a university spin-off company dedicated to developing and evaluating bone-targeting biologics for conditions such as Osteoporosis, Paget's disease, Osteoarthritis, and Bone Cancer. Their lead product, bisphosphonate conjugated Calcitonin (BP-CT), has demonstrated superior efficacy in preclinical models compared to existing treatments. Additionally, OMX offers advanced diagnostic services for measuring bone turnover, including high-resolution imaging and bone toxicology assays, on a fee-for-service basis. The company is actively seeking strategic partnerships for the optimization and clinical evaluation of their innovative therapies.Explore more
Popular SearchesOsteometabolix Pharmaceuticals IncSIC Code 28,283NAICS Code 32,325Show more
Osteometabolix Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Osteometabolix Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Osteometabolix Pharmaceuticals has new funding data
Check if Osteometabolix Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Check out if Osteometabolix Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when Osteometabolix Pharmaceuticals launches new products
Congratulate Masked Content for being promoted to Masked Content at Osteometabolix Pharmaceuticals
Click to see if Osteometabolix Pharmaceuticals had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Osteometabolix Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Osteometabolix Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Osteometabolix Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Osteometabolix Pharmaceuticals
Compare insights from companies similar to Osteometabolix Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Osteometabolix Pharmaceut...
<$5M
11-50
Private
-
-
JS
John SimonQuality and Regulatory Affairs Consultant - OMX
Company Profile Activity
Activity Insights
Osteometabolix Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Osteometabolix Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Osteometabolix Pharmaceuticals.
Osteometabolix Pharmaceuticals Tech Stack
A closer look at the technologies used by Osteometabolix Pharmaceuticals
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Osteometabolix Pharmaceuticals
Sign Up For FreeTo access detailed company insights
OMX is a university spin-off company dedicated to developing and evaluating bone-targeting biologics for conditions such as Osteoporosis, Paget's disease, Osteoarthritis, and Bone Cancer. Their lead product, bisphosphonate conjugated Calcitonin (BP-CT), has demonstrated superior efficacy in preclinical models compared to existing treatments. Additi... Read More
